Interstitial lung diseases (ILDs) encompass more than 100 conditions. They represent a heterogeneous group of acute or chronic lung diseases that are characterized—to varying degrees—by inflammation and uncontrolled connective tissue formation, leading to scarring and stiffening of the lungs. The initial presentation of IPF is insidious dyspnea on exertion and a dry cough; the prognosis is poor.
Autoren
- Melika Piric
- Prof. Dr. med. Philipp Markart
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Ischemic stroke: Are smaller or larger brain arteries affected?
Recent study findings on intravenous lysis therapy with fibrinolytic agents
- Interview
“On par with the gold standards for trauma”
- Psychology: Emotional Freedom Techniques (EFT)
Emotional Healing Through Tapping
- Systemic Lupus (SLE): What Does the Diagnosis and Treatment Toolbox Have to Offer?
Treat-to-Target – Consensus Recommendations for GC Tapering and the Use of DMARDs
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Psychedelic-assisted therapy
Current status of PAT
- Psoriasis and Obesity: Effects of Incretin-Based Therapies